Can Avanzanite accelerate NHS access to rare disease medicines in the UK?
Avanzanite appoints Sarah O'Connell to expand UK rare disease operations. The move strengthens its European commercialisation and patient access strategy.
Pharma & Biotech
Pharma & Biotech
Enhertu cut breast cancer recurrence risk by 53% against T-DM1, but will lung toxicity affect its use?
Enhertu wins EU approval after cutting invasive recurrence or death risk by 53% versus T-DM1. Lung toxicity remains a key consideration.
Pharma & Biotech
Pfizer’s TALZENNA and XTANDI cut prostate cancer progression risk by 52%, but who benefits most?
Pfizer wins FDA approval for TALZENNA plus XTANDI in earlier metastatic prostate cancer. See how a 52% progression-risk reduction changes treatment.
Pharma & Biotech
Bayer’s LYNKUET cut poor sleep reports sharply, but does that make it a menopause sleep treatment?
Bayer's LYNKUET showed improved self-reported sleep quality in a post-hoc Phase 3 analysis. The findings do not establish a separate sleep indication.
Pharma & Biotech
Aptar Pharma buys Pulmotree after two-year partnership, but can Kolibri unlock inhaled biologics?
Aptar Pharma acquires Pulmotree to advance Kolibri inhaler technology for complex medicines. Commercial success depends on validation and adoption.
Pharma & Biotech
Mirum’s ATEBRIOZ reduced abnormal bone volume in young children, but will the FDA expand its approval?
Mirum's ATEBRIOZ reduced abnormal bone volume in children aged 6 to under 12 with FOP. Can the results support FDA label expansion in 2027?
Pharma & Biotech
AimedBio’s $991m Boehringer Ingelheim cancer deal reaches human trials, but can BI 4060107 deliver?
AimedBio's BI 4060107 enters Phase 1 testing under a potential $991 million Boehringer Ingelheim deal. Safety and early activity remain unproven.
Pharma & Biotech
SERP-01 gene-editing results support Phase 2/3 plans for inherited lung and liver disease
Serapha Bio's SERP-01 gene editing restores protective protein levels in four AATD patients. Explore the early results and Phase 2/3 plans.
Pharma & Biotech
ORKA-001 shows strong psoriasis skin-clearance results as pivotal trials approach in 2027
Oruka Therapeutics' ORKA-001 achieves 61% complete skin clearance in Phase 2b psoriasis testing. Explore the results and Phase 3 plans.
Pharma & Biotech
Frontier’s FMC-376 triggered responses after KRAS inhibitor failure, but can its dual-state mechanism prevent resistance?
Frontier's FMC-376 achieved a 56% response rate in 18 evaluable lung cancer patients, including prior KRAS inhibitor users. Can larger trials confirm benefit?